DPP4 and heart failure: In light of the limited beneficial evidence on SGLT2 inhibitors and potential risk concerns with some of the DPP4 inhibitors, we undertook this study to examine how these two newer drug classes compare with each other in terms of associated risk of hospitalization for heart failure.